MiniSeqTM Sequencing System Makes Illumina NGS
Accessible for Every Laboratory
Infinium® XT Enables Highest Throughput
Genotyping to Date
Illumina Previews Project Firefly: A
Breakthrough Semiconductor-Based Sequencing System
Illumina, Inc. (NASDAQ: ILMN), the global leader in sequencing
and array-based technologies, today announced the newest addition
to its industry-leading next-generation sequencing (NGS) portfolio
with the launch of the MiniSeq Sequencing System. During its
presentation at the J.P. Morgan Healthcare Conference, Illumina
also introduced Infinium XT, and previewed Project Firefly, which
will lead to the commercialization of a new semiconductor-based
sequencing system.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160111006398/en/
Illumina's MiniSeq Sequencing System
(Photo: Business Wire)
“Illumina has a history of breaking down barriers in genomics by
making sequencing and genotyping easier to perform and less
expensive. The MiniSeq Sequencing System and Infinium XT
technologies build on this legacy and will enable researchers and
applied practitioners to unlock the power of the genome like never
before,” said Jay Flatley, CEO of Illumina. “With these new
products, and Project Firefly in development, we are excited about
enabling an increasing number of customers worldwide to unlock the
power of the genome.”
MiniSeq System
The new MiniSeq System makes Illumina’s trusted sequencing
technology accessible to all laboratories interested in performing
targeted sequencing. With push-button operation, the flexible
benchtop sequencer enables a broad range of DNA and RNA sequencing
applications, from examining single genes to entire pathways, in a
single run. Priced at $49,500 USD, and cost-efficient to run, the
affordable MiniSeq System allows virtually any laboratory to adopt
NGS, regardless of sample volume.
The research-use only MiniSeq System is designed and being
commercialized as part of a complete sequencing solution that
enables both experienced and new-to-NGS researchers to get results
quickly with an easy-to-use library-to-results workflow and onboard
data analysis for numerous assays. The sequencer is also able to
stream sequencing data to BaseSpace®, Illumina’s cloud and onsite
genomics computing environment. Compatible with a full suite of
Illumina library preparation solutions, and end-to-end support from
Illumina scientists and engineers, the MiniSeq System is an ideal
NGS workflow solution for many applications commonly performed by
molecular biologists, translational researchers in oncology, and
molecular pathologists.
The MiniSeq System will begin shipping early in the first
quarter of 2016. For more information, visit
www.illumina.com/miniseq.
Infinium XT
Infinium XT builds on the success of the Infinium product family
offering Illumina’s highest throughput array format to date. The
96-sample BeadChip offers laboratories the ability to perform
genotyping on larger numbers of samples, testing up to 50,000
markers per sample and enabling laboratories to scale up to one
million samples or more per year. This solution is ideally suited
for agrigenomics applications, which require low plexity assays,
especially for parentage, meat traceability, and genomic selection.
This product will also enable human applications, particularly for
biobanks and personalized medicine initiatives with large scale
targeted genotyping.
Infinium XT will begin shipping in the third quarter of
2016.
Project Firefly
Illumina also previewed a new sequencing system designed to
democratize NGS and truly enable the adoption of genomics
worldwide. The highly-reliable, easy-to-use NGS platform will offer
customers a low capital cost and plug and play installation. The
most integrated sequencer ever developed, the system will take
users from purified DNA to answers, making it the ideal tool for
virtually any laboratory. The stackable two module system will
minimize hands-on time for both library preparation and sequencing.
Leveraging Illumina digital fluidics technology, the first module
will make library preparation simple and efficient preparing eight
normalized samples in parallel on a library preparation cartridge.
A separate cartridge for sequencing, loaded into the second module,
will deploy a one channel version of Illumina’s
sequencing-by-synthesis chemistry on a semiconductor chip.
Sequencing data will seamlessly move to BaseSpace for analysis.
The new system will be superior to competing semiconductor-based
sequencing systems with a raw error rate of less than one percent,
data quality comparable to that of a HiSeq XTM Sequencing System.
With output of approximately 1.2G per run, the platform will be
ideal for numerous markets including academic research, oncology,
infectious disease, inherited disease, and reproductive health.
Illumina expects to commercialize this system in the second half
of 2017, priced at less than $30,000 USD for both modules. For
customers running eight samples at once, the company projects
per-sample consumable pricing near $100.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow
@illumina.
Forward-Looking Statements
This release contains forward looking statements that involve
risks and uncertainties, such as Illumina’s expectations regarding
the launch, shipping, or commercialization dates for new products;
performance characteristics for new products; and pricing for new
products. Important factors that could cause actual results to
differ materially from those in any forward-looking statements
include challenges inherent in developing, manufacturing, and
launching new products and services; the application of generally
accepted accounting principles, which are highly complex and
involve many subjective assumptions, estimates, and judgments; and
the other factors detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160111006398/en/
Illumina, Inc.Investors:Rebecca
Chambers858-255-5243rchambers@illumina.comorMedia:Gwen
Gordon858-882-6822pr@illumina.comorDavid Robertson, Europe, Middle
East and Africa+44 1223 824909drobertson@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Sep 2023 to Sep 2024